Xenetic Biosciences, Inc. — Form 10-Q
Filed August 6, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 28/100
What the filing says
Xenetic Biosciences signed a one-year consulting agreement dated April 29, 2026 with RND Pharm Intel DOO (Montenegro) and Dr. Grigorii Borisenko for services related to its DNase technology. Compensation is $125/hour for up to 240 billable hours, capped at $30,000 total. Services include analyzing clinical data, designing trial parameters, and estimating patient numbers for a planned DNase efficacy/safety study. The contract includes standard IP assignment, confidentiality, and conflict-of-interest provisions.
Why this rating
Small consulting contract (~0.6% of market cap) for technical advice on existing program. Routine operational expense; does not alter business trajectory or capital position.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.